Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 4, 2007 - Issue 4
Submit an article Journal homepage
3,833
Views
230
CrossRef citations to date
0
Altmetric
Technology Evaluation

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

Gregory I Frost Chief Scientific Officer, Halozyme Therapeutics, Inc., 11588 Sorrento Valley Road, CA, 92121, San Diego, +858 794 8889; +858 794 5730; [email protected]
, PhD
Pages 427-440 | Published online: 07 Aug 2007

Bibliography

  • SUPERSAXO A, HEIN WR, STEFFEN H: Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. (1990) 7:167-179.
  • DAY TD: The permeability of extracellular connective tissue and the nature of the interfibrillary substance. J. Physiol. (1952) 17:1-8.
  • TAYLOR AE, GRANGER DN: Exchange of macromolecules across the microcirculation. In: Handbook of Physiology. The Cardiovascular System. Microcirculation. Bethesda, MD: Am. Physiol. Soc. (1984) 4:467-520.
  • REED RK: Extracellular-lymphatic mechanisms in the control of extracellular fluid volume. Physiol. Rev. (1993) 73:1-78.
  • REED RK, LEPSOE S, WIIG H: Interstitial exclusion of albumin in rat dermis and subcutis in over- and dehydration. Am. J. Physiol. (1989) 257:1819-1827.
  • CRAIG AS, EIKENBERRY EF, PARRY DAD: Ultrastructural organization of skin: classification on the basis of mechanical role. Connect. Tissue Res. (1987) 16:213-223.
  • VERZIJL N, DEGROOT J, THORPE SR et al.: Effect of collagen turnover on the accumulation of advanced glycation end products. J. Biol. Chem. (2000) 275:39027-39031.
  • LAURENT UBG, DAHL LB, REED RK: Catabolism of hyaluronan in rabbit skin takes place locally, in lymph nodes and liver. Exp. Physiol. (1991) 76:695-703.
  • FRASER JR, LAURENT TC: . Ciba Found. Symp. (1989) 143:41-53; discussion 53-59, 281-285.
  • STARLING EH: On the absorption of fluids from the convective tissue spaces. J. Physiol. (1896) 19:312-326.
  • PORTER CJ, CHARMAN SA: Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci. (2000) 89:297-310.
  • FATOUROS A, LIDEN Y, SJOSTROM B: Recombinant factor VIII SQ-stability of VIII: C in homogenates from porcine, monkey and human subcutaneous tissue. J. Pharm. Pharmacol. (2000) 52:797-805.
  • MCMINN RMH (Ed.), Last's Anatomy: Regional and applied (9th Edition). London: Churchill Livingstone (1994).
  • ROSE EH, VISTNES LM, KSANDER GA: The panniculus carnosus in the domestic pig. Plast Reconstr. Surg. (1977) 59:94-97.
  • The Zitter Group: The managed care injectables index: spring (2005).
  • NUIJTEN MJ, ENGELFRIET P, DUIJN K, BRUIJN G, WIERZ D, KOOPMANSCHAP M: A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics (2001) 19:1051-1064.
  • GARDULF A, NICOLAY U: Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr. Opin. Allergy Clin. Immunol. (2006) 6:434-442.
  • LUNDIN J, KIMBY E, BJORKHOLM M et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood (2002) 100:768-773.
  • LAURENT UBG, DAHL LB, REED RK: Catabolism of hyaluronan in rabbit skin takes place locally, in lymph nodes and liver. Exp. Physiol. (1991) 76:695-703.
  • DURAN REYNALS F: Exaltation de l'activité du virus vaccinal par les extraits de certains organes. Comptes Rendus Hebdomadaires de Séances et Mémoires de la Société de Biologie (1928) 99:6-7.
  • CLAUDE A, DURAN-REYNALS F: Chemical properties of the purified spreading factor from testicle. J. Exp. Med. (1937) 65:661-670.
  • DURAN-REYNALS F: Further studies on the influence of testicle extract upon the effect of toxins, bacteria, and Viruses, and on the Shwartzman and Arthus phenomena. J. Exp. Med. (1933) 58:451-463.
  • DURAN-REYNALS F: A spreading factor in certain snake venoms and tts relation to their mode of action J. Exp. Med. (1939) 69:69-81.
  • DUTHIE ES, CHAIN EA: A mucolytic enzyme in testes extracts. Nature (1939) 144:977-978.
  • MEYER K, Hyaluronidases, In: BOYER PD (Ed.), The Enzymes. Academic Press, New York, (1971):307-320.
  • MEYER K, RAPPORT MM: Hyaluronidases. Adv. Enzymol. Relat. Subj. Biochem. (1952) 13:199-236.
  • MEYER K, HOFFMAN P, LINKER A: HYALURONIDASES. In: BOYER PD, LARDY H, MYRBÄCK K (Eds), The Enzymes, 2nd Edition, Volume 4, Academic Press, New York (1960):447-460.
  • RAPPORT MM, MYER K, LINKER A: Analysis of the products formed on hydrolysis of hyaluronic acid by testicular hyaluronidase. J. Am. Chem. Soc. (1951) 73:2416-2420.
  • HARRISON RA, GAUNT SJ: Multiple forms of ram and bull sperm hyaluronidase revealed by using monoclonal antibodies. J. Reprod. Fertil. (1988) 82:777-785.
  • Harrison RA: Hyaluronidase in ram semen. Quantitative determination, and isolation of multiple forms. Biochem. J. (1988) 252:865-874.
  • BORDERS CL, RAFTERY MA: Purification and partial characterization of testicular hyaluronidase. J. Biol. Chem. (1968) 243:3756-37562.
  • LATHROP WF, CARMICHAEL EP, MYLES DG, PRIMAKOFF P: cDNA cloning reveals the molecular structure of a sperm surface protein, PH-20, involved in sperm-egg adhesion and the wide distribution of its gene among mammals. J. Cell Biol. (1990) 111:2939-2949.
  • GMACHL M, KREIL G: Bee venom hyaluronidase is homologous to a membrane protein of mammalian sperm. Proc. Natl. Acad. Sci. USA (1993) 90:3569-3573.
  • GMACHL M, SAGAN S, KETTER S, KREIL G: The human sperm protein PH-20 has hyaluronidase activity. FEBS Lett. (1993) 336:545-548.
  • CSOKA AB, FROST GI, STERN R: The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. (2001) 20:499-508.
  • FROST GI, CSOKA AB, WONG T, STERN R: Purification, cloning, and expression of human plasma hyaluronidase. Biochem. Biophys. Res. Commun. (1997) 236:10-15.
  • CHERR GN, MEYERS SA, YUDIN AI et al.: The PH-20 protein in cynomolgus macaque spermatozoa: identification of two different forms exhibiting hyaluronidase activity. Dev. Biol. (1996) 175:142-153.
  • GACESA P, CIVILL ND, HARRISON RA: PH-20 and sperm hyaluronidase: a conceptual conundrum in mammalian fertilization. Biochem. J. (1994) 303:335-336.
  • MEYER MF, KREIL G, ASCHAUER H: The soluble hyaluronidase from bull testes is a fragment of the membrane-bound PH-20 enzyme. FEBS. Lett. (1997) 413:385-388.
  • ARMING S, STROBL B, WECHSELBERGER C, KREIL G: In vitro mutagenesis of PH-20 hyaluronidase from human sperm. Eur. J. Biochem. (1997) 247:810-814.
  • FROST GI, STERN R: A microtiter-based assay for hyaluronidase activity not requiring specialized reagents. Anal. Biochem. (1997) 251:263-269.
  • KEISER HD, HATCHER VB: The effect of contaminant proteases in testicular hyaluronidase preparations on the immunological properties of bovine nasal cartilage proteoglycan. Connect. Tissue Res. (1979) 6:229-233.
  • DOCTOR VM, SPENCE H, CARROLL EY: Isolation and properties of a new anticoagulant protein from commercial bovine testicular hyaluronidase. Thromb. Res. (1883) 30:565-571.
  • HYUGA M, KODAMA R, EGUCHI G: Basic fibroblast growth factor as one of the essential factors regulating lens transdifferentiation of pigmented epithelial cells. Int. J. Dev. Biol. (1993) 37:319-326.
  • HOUCK JC, CHANG CM: Permeability factor contaminating hyaluronidase preparations. Inflammation (1979) 4:447-451.
  • OETTL M, HOECHSTETTER J, ASEN I, BERNHARDT BUSCHAUER GA: Comparative characterization of bovine testicular hyaluronidase and a hyaluronate lyase from Streptococcus agalactiae in pharmaceutical preparations. Eur. J. Pharm. Sci. (2003) 18:267-277.
  • BOOKBINDER LH, HOFER A, HALLER MF et al.: A recombinant human enzyme for enhanced interstitial transport of therapeutics. J. Control. Release (2006) 114:230-241.
  • HECHTER O: Studies on spreading factors: I. The importance of mechanical factors in hyaluronidase action in skin. J. Exp. Med. (1947) 85:77-97.
  • FESSLER JH: Mode of action of testicular hyaluronidase. Biochem. J. (1960) 76:132-135.
  • HECHTER O, DOPKEEN SK, YUDELL MH: The clinical use of hyaluronidase in hypodermoclysis. J. Peds. (1947) 30:645-656.
  • LINSENMAYER TF: Collagen. In: Cell Biology of Extracellular Matrix. Hay ED (Ed.), New York: Plenum (1981):5-37.
  • WOLF RA, CHAUNG LY, O'HARA D, SMITH TW, MULLER JE: The serum kinetics of bovine testicular hyaluronidase in dogs, rats and humans. J. Pharmacol. Exp. Ther. (1982) 222:331-337.
  • TAMMI R, SAAMANEN AM, MAIBACH HI, TAMMI M: J. Invest. Dermatol. (1991) 97:126-130.
  • LAURENT TC, FRASER JRE: In: Degradation of Bioactive Substances: Physiology and Pathophysiology. Henriksen JH (Ed.), CRC Press, Boca Raton, FL (1991):249-265.
  • HARRIS EN, WEIGEL JA, WEIGEL PH: Endocytic function, glycosaminoglycan specificity, and antibody sensitivity of the recombinant human 190-kDa hyaluronan receptor for endocytosis (HARE). J. Biol. Chem. (2004) 279:36201-36209.
  • HECHTER O: Reconstitution of the dermal barrier to fluid diffusion folIowing administration of hyaluronidase. Proc. Soc. Exp. Biol. Med. (1948) 67:343-344.
  • MUCKENSCHNABEL I, BERNHARDT G, SPRUSS T, BUSCHAUER A. Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy. Cancer Lett. (1998) 131(1):71-84.
  • Federal Register: 35 (1970):14800-14801.
  • JAWORSKI A, FARLEY JE Jr: Hyaluronidase in administration of fluids. Am. J. Dis. Child. (1950) 79:59-64.
  • BURKET EC, GYÖRGY P: Clinical observations on the use of hyaluronidase. Pediatrics (1949) 3:56-63.
  • ATKINSON WS: Use of hyaluronidase with local anesthesia in ophthalmology; preliminary report. Arch. Ophthal. (1949) 42:628-633.
  • TASSMAN IS: The use of hyaluronidase in ophthalmology. Am. J. Ophthalmol. (1952) 35:683-686.
  • ALWITRY A, CHAUDHARY S, GOPEE K, BUTLER TK, HOLDEN R: Effect of hyaluronidase on ocular motility in sub-Tenon's anesthesia: randomized controlled trial. J. Cataract Refract. Surg. (2002) 8:11420-1423.
  • KALLIO H, PALOHEIMO M, MAUNUKSELA EL: Hyaluronidase as an adjuvant in bupivacaine-lidocaine mixture for retrobulbar/peribulbar block. Anesth. Analg. (2000) 91:934-937.
  • JEHAN FS, HAGAN JC III, WHITTAKER TJ, SUBRAMANIAN M: Diplopia and ptosis following injection of local anesthesia without hyaluronidase. J. Cataract Refract. Surg. (2001) 11:1876-1879.
  • HAMADA S, DEVYS JM, XUAN TH et al.: Role of hyaluronidase in diplopia after peribulbar anesthesia for cataract surgery. Ophthalmology (2005) 112:879-882.
  • Intravenous Nurses Society: Infiltration/Extravasation. J. Intravenous Nursing (1998) 21 (1S):S36-S37.
  • GOOLSBY TV, LOMBARDO FA: Extravasation of chemotherapeutic agents: prevention and treatment. Semin. Oncol. (2006) 33:139-143 (Review).
  • BERTELLI G, DINI D, FORNO GB et al.: Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. J. Cancer Res. Clin. Oncol. (1994) 120:505-506.
  • LAURIE SWS, WILSON KL, KERNAHAN DA, BAUER DS, VISTNES LM: Intravenous extravasation injuries: the effectiveness of hyaluronidase in their treatment. Ann. Plastic Surg. (1984) 13:192-194.
  • DORR RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev. (1990) 4:41-60.
  • RASZKA WV Jr, KUESER TK, SMITH FR, BASS JW: The use of hyaluronidase in the treatment of intravenous extravasation injuries. J. Perinatol. (1990) 10:146-149.
  • KUMAR MM, SPRUNG J: The use of hyaluronidase to treat mannitol extravasation. Anesth. Analg. (2003) 97:1199-2000.
  • ZENK KE, DUNGY CI, GREENE GR: Nafcillin extravasation injury. Use of hyaluronidase as an antidote. Am. J. Dis. Child. (1981) 135:1113-1114.
  • COCHRAN ST, BOMYEA K, KAHN M: Treatment of iodinated contrast material extravasation with hyaluronidase. Acad. Radio. (2002):S544-S546.
  • SIMON NL, NARIN L: The effect of hyaluronidase on the absorption of a subcutaneously deposited radiopaque substance. Amer. J. Roentgen. (1949) 61:91-94.

Patents

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.